ARROWHEAD PHARMACEUTICALS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ARROWHEAD PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $5.70M, a 2454.71% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $1.97M, a 24.86% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $5.10M, a 704.10% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $223.00K, a 42.53% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $3.98M, a 66.72% increase from fiscal 2024.
- ARROWHEAD PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $2.39M, a 21.77% decline from fiscal 2023.
- ARROWHEAD PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $3.05M, a 41.10% decline from fiscal 2022.
- ARROWHEAD PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $5.18M, a 54.14% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $5.70M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $1.97M 10-Q · filed 2026-08-04 | |
| 2025-12-31 | $5.10M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $3.98M 10-K · filed 2025-11-25 | |
| 2025-06-30 | $223.00K 10-Q · filed 2026-08-04 | |
| 2025-03-31 | $2.62M 10-Q · filed 2026-08-04 | |
| 2024-12-31 | $634.00K 10-Q · filed 2026-08-04 | |
| 2024-09-30 | $2.39M 10-K · filed 2025-11-25 | |
| 2024-06-30 | $388.00K 10-Q · filed 2025-08-07 | |
| 2024-03-31 | $1.51M 10-Q · filed 2025-08-07 | |
| 2023-12-31 | $267.00K 10-Q · filed 2025-08-07 | |
| 2023-09-30 | $3.05M 10-K · filed 2025-11-25 | |
| 2023-06-30 | $1.14M 10-Q · filed 2024-08-08 | $3.14M derived: sum of 4 quarters · filed 2024-11-26 |
| 2023-03-31 | $520.00K 10-Q · filed 2024-08-08 | $2.60M derived: sum of 4 quarters · filed 2024-11-26 |
| 2022-12-31 | $576.00K 10-Q · filed 2024-08-08 | $3.62M derived: sum of 4 quarters · filed 2024-11-26 |
| 2022-09-30 | $904.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-26 | $5.18M 10-K · filed 2024-11-26 |
| 2022-06-30 | $599.00K 10-Q · filed 2023-08-07 | $5.10M derived: sum of 4 quarters · filed 2023-11-29 |
| 2022-03-31 | $1.54M 10-Q · filed 2023-08-07 | $7.25M derived: sum of 4 quarters · filed 2023-11-29 |
| 2021-12-31 | $2.15M 10-Q · filed 2023-08-07 | $8.35M derived: sum of 4 quarters · filed 2023-11-29 |
| 2021-09-30 | $815.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-29 | $11.30M 10-K · filed 2023-11-29 |
| 2021-06-30 | $2.76M 10-Q · filed 2022-08-04 | $11.49M derived: sum of 4 quarters · filed 2022-11-28 |
| 2021-03-31 | $2.63M 10-Q · filed 2022-05-10 | $10.87M derived: sum of 4 quarters · filed 2022-11-28 |
| 2020-12-31 | $5.10M 10-Q · filed 2022-02-02 | $9.57M derived: sum of 4 quarters · filed 2022-11-28 |
| 2020-09-30 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-11-28 | $7.47M 10-K · filed 2022-11-28 |
| 2020-06-30 | $2.13M 10-Q · filed 2021-08-05 | $8.30M derived: sum of 4 quarters · filed 2021-11-22 |
| 2020-03-31 | $1.33M 10-Q · filed 2021-05-04 | $8.93M derived: sum of 4 quarters · filed 2021-11-22 |
| 2019-12-31 | $3.00M 10-Q · filed 2021-02-04 | $10.27M derived: sum of 4 quarters · filed 2021-11-22 |
| 2019-09-30 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-22 | $8.28M 10-K · filed 2021-11-22 |
| 2019-06-30 | $2.77M 10-Q · filed 2020-08-05 | $8.07M derived: sum of 4 quarters · filed 2020-11-23 |
| 2019-03-31 | $2.67M 10-Q · filed 2020-05-07 | $6.14M derived: sum of 4 quarters · filed 2020-11-23 |
| 2018-12-31 | $1.00M 10-Q · filed 2020-02-05 | $3.66M derived: sum of 4 quarters · filed 2020-11-23 |
| 2018-09-30 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-23 | $2.66M 10-K · filed 2020-11-23 |
| 2018-06-30 | $838.93K 10-Q · filed 2019-08-05 | |
| 2018-03-31 | $193.13K 10-Q · filed 2019-05-08 | |
| 2017-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-11-25 | $271.93K 10-K · filed 2019-11-25 |
| 2017-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-08-03 | |
| 2016-09-30 | $108.33K derived: 10-K 12 month − 10-Q 9 month · filed 2018-12-11 | $133.87K 10-K · filed 2018-12-11 |
| 2016-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-09 | $84.29K derived: sum of 4 quarters · filed 2017-12-12 |
| 2016-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-05-10 | $84.29K derived: sum of 4 quarters · filed 2017-12-12 |
| 2015-12-31 | $25.54K 10-Q · filed 2016-02-09 | $114.44K derived: sum of 4 quarters · filed 2017-12-12 |
| 2015-09-30 | $58.74K derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-12 | $101.87K 10-K · filed 2017-12-12 |
| 2015-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-08-04 | $403.86K derived: sum of 4 quarters · filed 2016-12-14 |
| 2015-03-31 | $30.15K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-05-11 | $534.47K derived: sum of 4 quarters · filed 2016-12-14 |
| 2014-12-31 | $12.98K 10-Q · filed 2015-02-09 | $2.42M derived: sum of 4 quarters · filed 2016-12-14 |
| 2014-09-30 | $360.74K derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-14 | $2.73M 10-K · filed 2016-12-14 |
| 2014-06-30 | $130.61K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-08-12 | |
| 2014-03-31 | $1.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-05-06 | |
| 2013-12-31 | $326.92K 10-Q · filed 2014-02-04 | |
| 2013-09-30 | $2.58K 10-K · filed 2015-12-14 | |
| 2012-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-11-25 | $23.83K 10-K · filed 2014-11-25 |
| 2012-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-08-13 | $23.83K derived: sum of 4 quarters · filed 2014-05-06 |
| 2012-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-05-08 | |
| 2011-12-31 | $23.83K 10-Q · filed 2012-02-09 | |
| 2011-09-30 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2014-05-06 | $13.88K 10-Q · filed 2014-05-06 |
| 2010-09-30 | $7.63K 10-Q · filed 2014-05-06 | |
| 2008-09-30 | $290.03K 10-Q · filed 2014-05-06 | |
| 2007-09-30 | $434.73K 10-Q · filed 2014-05-06 | |
| 2006-09-30 | $341.54K 10-Q · filed 2014-05-06 | |
| 2004-09-30 | $15.00K 10-Q · filed 2014-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |